Teratogenicity with angiotensin II receptor antagonists in pregnancy

Journal of Endocrinological Investigation

Volumn 28, Issue 2, 2005, Pages 1029-1031

  Boix, E ^a,b   Zapater, P ^a   Pico A ^a   Moreno, O ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b NONE   (Spain)

Author keywords

ACE inhibitors; Angiotensin II receptor antagonists; Irbesartan; Pregnancy; Teratogenicity

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; INSULIN; IRBESARTAN; METHYLDOPA;

ADULT; AGENESIS; ANAMNESIS; ARTICLE; CASE REPORT; EXENCEPHALY; FEMALE; FETOTOXICITY; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; PREGNANCY; PREGNANCY DISORDER; PREGNANCY TOXEMIA; TERATOGENICITY; VITAMIN SUPPLEMENTATION;

EID: 33144461691     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345344     Document Type: Article

References (22)

1. Guignard JP, Burgener F, Calame A. Persistent anuria in a neonate: a side effect of captopril? Int J Pediatr Nephrol 1981, 2: 133.
2. Barr M, Cohen M. ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. Teratology 1991, 44: 485-95.
3. Barr M. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology, 1994, 50: 399-409.
4. Briggs GG, Nageotte MP. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother 2001, 35: 859-61.
5. Hinsberger A, Wingen AM, Hoyer PF. Angiotensin II receptor inhibitors in pregnancy. Lancet 2001, 357: 1620.
6. Lambot MA, Vermeylen D, Noel JC. Angiotensin II receptor antagonists in pregnancy. Lancet 2001, 357: 1619-21.
7. Martinovic J, Benachi A, Laurent N. Fetal toxic effects and angiotensin II receptor antagonists. Lancet 2001, 358: 241-2.
8. Saji H, Yamanaka M, Hagiwara A, Ijiri R. Losartan and fetal toxic effects. Lancet 2001, 357: 363.
9. Schaefer C. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol 2003, 67: 591-4.
10. Cox RM, Anderson JM, Cox P. Defective embryogenesis with angiotensin II receptor antagonists in pregnancy. BJOG 2003, 110: 1038-40.
11. Berkane N, Carlier P, Verstraete L, Mathieu E, Heim N, Uzan S. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res A Clin Mol Teratol 2004, 70: 547-9.
12. Teoh TG, Redman CW. Management of pre-existing disorders in pregnancy: hypertension. Prescr J 1996, 36: 28-36.
13. Spence SG, Cukierski MA, Manson JM, Robertson RT, Eydelloth RS. Evaluation of the reproductive and developmental toxicity of the AT1-selective angiotensin II receptor antagonist losartan in rats. Teratology 1995, 51: 383-97.
14. Chung NA, Lipp GYH, Beevers M, Beevers DG. Angiotensin II receptor inhibitors in pregnancy. Lancet 2001, 357: 1620-1.
15. De Gasparo M, Levens NR. Pharmacology of angiotensin II receptors in the kidney. Kidney Int 1994, 46: 1486-91.
16. Guron G, Friberg P. An intact renin-angiotensin system is a prerequisite for normal renal development. J Hypertens 2000, 18: 123-37.
17. Holstein A, Plaschke A, Egberts EH. Use of insulin glargine during embryogenesis in a pregnant woman with type 1 diabetes. Diabet Med 2003, 20: 779-80.
18. Devlin JT, Hothersall L, Wilkis JL. Use of insulin glargine during pregnancy in a type 1 diabetic woman. Diabetes Care 2002, 25: 1095-6.
19. Hofmann T, Horstmann G, Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int J Toxicol 2002, 21: 181-9.
20. Collins R, Yusuf S, Peto R. Overview of randomized trials of diuretics in pregnancy. Br Med J 1985, 290: 17-23.
21. Bayoumeu F, Verspyck E. Prevention strategies during pregnancy. J Gynecol Obstet Biol Reprod (Paris) 2004, 33: 17-28.
22. Krafft A, Breymann C. Haemoglobinopathy in pregnancy: diagnosis and treatment. Curr Med Chem 2004, 11: 2903-9.